Association of citalopram with congenital anomalies: A meta-analysis


OBJECTIVE The antenatal use of citalopram, a widely prescribed selective serotonin reuptake inhibitor, has been suspected to be associated with congenital, particularly cardiac, anomalies. This study aimed to prove the association between citalopram use and congenital anomalies. METHODS We searched the English literature from July 1998 to July 2015, by using the search terms ' citalopram', ' pregnancy', ' birth defects', ' congenital anomalies', and ' malformations' in PubMed, Embase, Web of Science, and the Cochrane Library. RESULTS Eight eligible articles were analyzed including a total of 1,507,896 participants. The odds ratio (OR) of major malformations associated with citalopram use during pregnancy was 1.07 (95% confidence interval [CI], 0.98 to 1.17). Concerning cardiac malformations, the OR for all included studies was 1.31 (95% CI, 0.88 to 1.93). The analysis of cardiac malformations was repeated to reduce heterogeneity after excluding one outlier study (OR, 1.03; 95% CI, 0.84 to 1.26). CONCLUSION From our data, it can be concluded that citalopram use is not associated with major birth defects. However, physicians should carefully weigh the benefits against the potential risks of citalopram use, and counsel patients accordingly.

DOI: 10.5468/ogs.2017.60.2.145

5 Figures and Tables

Cite this paper

@inproceedings{Kang2017AssociationOC, title={Association of citalopram with congenital anomalies: A meta-analysis}, author={Hyun-Hye Kang and Ki Hoon Ahn and Soon-Cheol Hong and Bo Yong Kwon and Eun Hee Lee and Ji-Sung Lee and M J Oh and Hai-Joong Kim}, booktitle={Obstetrics & gynecology science}, year={2017} }